Table 1.

Sorafenib HCC Assessment Randomized Protocol (SHARP) [1] and Asia-Pacific [2] study

	SHARP [1]		Asia-Pacific [2]
Endpoint	Sorafenib vs placebo		Sorafenib vs placebo
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
OS	10.7 vs 7.9 months, 0.69 (0.55 to 0.87)	< 0.001	6.5 vs 4.2 months, 0.68 (0.50 to 0.93)	0.014
TTSP	1.08 (0.88 to 1.31)	0.768	0.90 (0.67 to 1.22)	0.50
TTP	5.5 vs 2.8 months, 0.58 (0.45 to 0.74)	< 0.001	2.8 vs 1.4 months, 0.57 (0.42 to 0.79)	< 0.001
RR	2% vs 1%		3.3% vs 1.3%

OS = overall survival; RR = response rate; TTP = time to tumor progression; TTSP = time to symptomatic progression.